admin, Author at Xeltis

Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages...

admin In Latest News

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership...

admin In Latest News

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows...

admin In Clinical Trials, Latest News

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent,...

admin In Events, Latest News

Xeltis Announces Latest Results from aXess™ Trials to be Presented at 46th Annual Charing Cross Symposium

Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who...

admin In Publications

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living...

admin In Publications

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR

Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial...

admin In Publications

Excellent performance and safety data on Xeltis bio-restorative technology published

Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative...

admin In Events

Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern

Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve...

admin In Finances

Xeltis’ closes €10.5 million Series D financing

Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The...

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.